ASPIRIN AND SECONDARY MORTALITY AFTER MYOCARDIAL INFARCTION
References (6)
- et al.
A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction
Br Med J
(1974) Aspirin in coronary heart disease
J Chron Dis
(1976)
Cited by (243)
Optimal Medical Therapy for Chronic Coronary Disease in 2024: Focus on Antithrombotic Therapy
2024, Medical Clinics of North AmericaAspirin for cardiovascular disease prevention among adults in the United States: Trends, prevalence, and participant characteristics associated with use
2021, American Journal of Preventive CardiologyClinical decision-making: Challenging traditional assumptions
2021, International Journal of CardiologyCitation Excerpt :Statistical significance was not achieved in this study published in 1974, paving the way for the subsequent trials. The beneficial effects of aspirin were initially shown in the secondary prevention setting in patients with a history of MI or unstable angina [3–5], and subsequently in patients with a history of stroke or transient ischemic attack as well [6,7]. A meta-analysis of 25 randomized trials looking at secondary prevention of cardiovascular disease (CVD) demonstrated a 15% reduction in vascular mortality and 30% reduction in non-fatal vascular events, consisting of MI and stroke, in patients allocated to antiplatelet therapy without a difference in the beneficial effects between patients allocated to lower dose (300–325 mg /day) versus higher dose of aspirin [8].
Long-term use of cardiovascular drugs challenges for research and for patient care
2015, Journal of the American College of CardiologyCitation Excerpt :Although the average follow-up in RCTs is limited, these medications are often administered open-endedly over many years. Table 2(11,12,17,23–49) shows an overview of some landmark RCTs that demonstrated the efficacy of aspirin, statins, beta-blockers, and ACE inhibitors in post-MI (and stable CHD) patients. A good example of this problem is a meta-analysis published in 2010 on the use of statins as primary and secondary prevention, in which the median follow-up across 26 trials was 4.9 years (2).
Sudden cardiac death from the perspective of coronary artery disease
2014, Mayo Clinic ProceedingsCitation Excerpt :Treating all patients who have experienced MI with aspirin decreases all-cause mortality and has the additional benefit of reducing the likelihood of ischemic stroke and reinfarction through antiplatelet effects.94 In one early trial evaluating the role of aspirin in secondary prevention after MI, patients randomly assigned to aspirin for 1 year had an overall decrease in total mortality and a hospital readmission rate of 28% compared with those given a placebo (P<.05).95 β-Blockers also reduce all-cause mortality and the risk of reinfarction in the post-MI period and may decrease the rates of SCD by 40% to 55%.96
Antiplatelet Therapy
2011, Preventive Cardiology: Companion to Braunwald's Heart Disease Expert Consult - Online and Print